TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2020 Feb 21

PMID 32077004

Citations 10

Authors

Jiao Wu

Yunpeng Wang

Zheng Jiang

Affiliations

Soon will be listed here.

Abstract

Background: TNFSF9 gene has been found to play an anti-tumor role and regulate the function of immune cells. However, the prognostic role of TNFSF9 in pancreatic cancer and its relationship with immune cell infiltration have not been studied.

Methods: We used Oncomine, UALCAN, and GEPIA databases to analyze the expression of TNFSF9 in pancreatic cancer. We used Kaplan-Meier plotters, GEPIA, and UALCAN to evaluate the effect of TNFSF9 on clinical prognosis. We further used TIMER to study the correlation between TNFSF9 and cancer immune infiltrate cells. In addition, we used GEPIA to analyze the correlation between TNFSF9 expression and gene markers of immune infiltrate cells.

Results: TNFSF9 mRNA expression level was remarkably increased in pancreatic cancer than that in normal tissues (both P < 0.05). In addition, high TNFSF9 expression was significantly related to poor overall survival (OS) and relapse-free survival (RFS) in pancreatic cancer (OS HR = 2.02, P = 0.0012; RFS HR = 2.63, P = 0.022). Moreover, high TNFSF9 expression in pancreatic cancer patients was associated with worse OS in stage 1 to 2 but not stage 3 and stage 4. Specifically, TNFSF9 expression and CD8 T cell infiltration of pancreatic cancer was negatively correlated. TNFSF9 expression showed strong correlations with M1 macrophages in pancreatic cancer.

Conclusions: Our results suggest that TNFSF9 is associated with prognosis and CD8 T cell infiltration levels in patients with pancreatic cancer. Further, TNFSF9 expression potentially contributes to the modulation of M1 polarization of macrophages. These findings indicate that TNFSF9 can be serves as a prognostic biomarker in determining the prognosis of pancreatic cancer and is associated with different types of phenotypes of immune cell infiltration.

Citing Articles

Discovery of a new mitophagy-related gene signature for predicting the outlook and immunotherapy in triple-negative breast cancer.

Liu G, Yu G, Yin D, Ma J Sci Rep. 2025; 15(1):6794.

PMID: 40000809 PMC: 11861672. DOI: 10.1038/s41598-025-91613-9.

Is Associated with Favorable Tumor Immune Microenvironment in Patients with Renal Cell Carcinoma Who Are Treated with the Combination Therapy of Nivolumab and Ipilimumab.

Isoda B, Kandori S, Sazuka T, Kojima T, Nitta S, Shiga M Int J Mol Sci. 2024; 25(13).

PMID: 39000552 PMC: 11242552. DOI: 10.3390/ijms25137444.

The potential use and experimental validation of genomic instability-related lncRNA in pancreatic carcinoma.

Xia X, Zhao S, Song X, Zhang M, Zhu X, Li C Medicine (Baltimore). 2023; 102(37):e35300.

PMID: 37713870 PMC: 10508516. DOI: 10.1097/MD.0000000000035300.

Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study.

Wen C, Zhang L, Yang Y, Jin Y, Ren D, Zhang Z Int J Surg. 2023; 109(7):1941-1952.

PMID: 37026827 PMC: 10389500. DOI: 10.1097/JS9.0000000000000264.

A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and TNFSF9.

Li L, Yang M, Yu J, Cheng S, Ahmad M, Wu C Int J Mol Sci. 2022; 23(18).

PMID: 36142828 PMC: 9504056. DOI: 10.3390/ijms231810916.

References

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

Daley D, Mani V, Mohan N, Akkad N, Pandian G, Savadkar S . NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. J Exp Med. 2017; 214(6):1711-1724. PMC: 5461004. DOI: 10.1084/jem.20161707. View

De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H . Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011; 208(3):469-78. PMC: 3058573. DOI: 10.1084/jem.20101876. View

Ochi A, Nguyen A, Bedrosian A, Mushlin H, Zarbakhsh S, Barilla R . MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012; 209(9):1671-87. PMC: 3428946. DOI: 10.1084/jem.20111706. View

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T . CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004; 28(1):e26-31. DOI: 10.1097/00006676-200401000-00023. View

Wang X, Luo G, Zhang K, Cao J, Huang C, Jiang T . Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. Cancer Res. 2018; 78(16):4586-4598. DOI: 10.1158/0008-5472.CAN-17-3841. View

Deshmukh S, Tyagi N, Khan M, Srivastava S, Al-Ghadhban A, Dugger K . Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages. Sci Rep. 2018; 8(1):12000. PMC: 6086900. DOI: 10.1038/s41598-018-30437-2. View

Shen Y, Gan Y, Gao H, Fan Y, Wang Q, Yuan H . TNFSF9 exerts an inhibitory effect on hepatocellular carcinoma. J Dig Dis. 2017; 18(7):395-403. DOI: 10.1111/1751-2980.12489. View

Dharmadhikari B, Wu M, Abdullah N, Rajendran S, Ishak N, Nickles E . CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology. 2016; 5(4):e1113367. PMC: 4839363. DOI: 10.1080/2162402X.2015.1113367. View

10.

Langstein J, Michel J, Fritsche J, Kreutz M, Andreesen R, Schwarz H . CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling. J Immunol. 1998; 160(5):2488-94. View

11.

Maniar A, Zhang X, Lin W, Gastman B, Pauza C, Strome S . Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010; 116(10):1726-33. PMC: 3324253. DOI: 10.1182/blood-2009-07-234211. View

12.

Mardiana S, John L, Henderson M, Slaney C, Von Scheidt B, Giuffrida L . A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. Cancer Res. 2017; 77(6):1296-1309. DOI: 10.1158/0008-5472.CAN-16-1831. View

13.

Kwon B . CD137-CD137 Ligand Interactions in Inflammation. Immune Netw. 2010; 9(3):84-9. PMC: 2803301. DOI: 10.4110/in.2009.9.3.84. View

14.

Dimberg J, Hugander A, Wagsater D . Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncol Rep. 2006; 15(5):1197-200. View

15.

Salih H, Kosowski S, Haluska V, Starling G, Loo D, Lee F . Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells. J Immunol. 2000; 165(5):2903-10. DOI: 10.4049/jimmunol.165.5.2903. View

16.

Qian Y, Pei D, Cheng T, Wu C, Pu X, Chen X . CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer. Med Oncol. 2015; 32(3):44. DOI: 10.1007/s12032-015-0499-9. View

17.

Rhodes D, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B . Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007; 9(2):166-80. PMC: 1813932. DOI: 10.1593/neo.07112. View

18.

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

19.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

20.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View